AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
PSNL

Personalis Inc. Common Stock (PSNL) fair value

Healthcare · Diagnostics & Research · NASDAQ · United States
$15.85+0.19%
Market cap $1.7BNext earnings 2026-11-03Updated Oct 24, 2026
Add earnings to calendarGoogle
Our verdict
Trades 66% above our fair value
Price
$15.85
Model fair valueConfidence: low
about $9.54
Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionPersonalis Inc. Common Stock (PSNL)
Fair value
Not available
ACCE price target
$13.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 12 Oct 2026, 00:00 CEST.
Price used: $15.85 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
48
out of 100
Analysts
20% buy
5 covering
P/E
0.0x
forward 0.0x
1-year return
+67.7%
Dividend yield
0.00%

Personalis Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Personalis sells whole-genome and exome sequencing services and its NeXT Personal platform, which uses tumour-informed assays to track cancer recurrence from a blood draw. The business is clearly early: revenue grew 30% but gross margin is only 12.7% and operating margin is -150.3%, so the case rests on whether volume can scale faster than the cost base. The near-term swing factor is adoption of the MRD (molecular residual disease) test in clinical trials and reimbursed oncology settings, and any evidence that test volumes are converting into higher gross margin. At a $1.7B market capitalisation with no index membership and a 48/100 score, the stock is priced for that conversion to happen, and the data here does not yet show it. Worth a deeper look only if the next filings show gross margin moving materially higher alongside continued top-line growth.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
  • high
    Severe profitability collapse
    Operating margin -150.2%, net margin -153.8%. Company burns cash despite 30% revenue growth. FCF negative $56M annually.
  • high
    Insider selling pressure
    Last 10 disclosed transactions: $3.36M in sales, $0 in buys. Insiders exiting despite 26.1% ownership stake.
  • moderate
    Valuation disconnect from fundamentals
    P/S 24.5x on negative earnings and margins. ACCE fair value $13.00 vs current $16.00; model range $7-$18 reflects high uncertainty.
  • moderate
    Growth deceleration long-term
    5-year revenue CAGR only 2.3% despite recent 30% YoY and 44.5% QoQ. Suggests recent spike may not be sustainable.

AI research notes

AI-assisted·How I use AIWritten Oct 12, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Revenue surged 30.0% year over year, demonstrating strong demand for the company's core offerings.
  • Balance sheet remains sound with debt to equity of only 0.16, limiting financial distress risk.
  • Only 20% of analysts rate the stock Buy or Strong Buy, suggesting limited downside from consensus.
Why it could disappoint
  • Company burned $56M in free cash flow over the last 12 months with no clear path to profitability.
  • Share count exploded 50.6% in the last fiscal year, massively diluting existing shareholders.
  • Earnings missed expectations by 20.0% most recently, and analyst mean price target sits 5.2% below current price.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Nov 3, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where PSNL's valuation models land
Price
$15.85
Model fair valueConfidence: low
about $9.54
Model
Fair value
Upside
Analyst consensus
Sales comps
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bearish20% buy · 5 covering analysts
● Strong buy 1● Buy 0● Hold 4● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+1.3%
1 month
-3.1%
3 months
+34.6%
6 months
+159.8%
YTD
+99.1%
1 year
+67.7%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
12 Oct 2026, 00:00 CESTACCE price target$13.00first publication$16.00

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full PSNL page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth52Value11Quality31Momentum97Total48
Valuation
Trailing P/E
0.0x
Forward P/E
0.0x
PEG
no data
P/B
7.43x
EV / Revenue
22.6x
Book value/sh
$2.21
Enterprise value
$1.6B
Profitability
ROE
-50.3%
FCF yield
-4.70%
ROIC
-22.1%
Health and risk
Debt / equity
0.15
Dividend yield
0.00%
Beta
2.32

Price

+63.7% · 1Y

Ask anything about PSNL

Answered from Personalis Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 0.0x0.0xhigh 53.8x
ROEbetter than 0% of peers
low -50%-50%high 46%
Div yieldbetter than 83% of peers
low 0.0%0.0%high 2.9%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
PSNL Personalis Inc. Common Stock$15.85----50.3%3148
WGS GeneDx Holdings Corp. Class A Common Stock$56.15----40.8%4333
NEO NeoGenomics Inc. Common Stock$16.59----6.3%3956
VIMIAN.ST Vimian Group AB (publ)kr 40.90kr 2658% above53.8x5.3%7163
OPK OPKO Health Inc. Common Stock$1.63----5.9%3142
CSTL Castle Biosciences Inc. Common Stock$33.08----4.2%4755
CBAV.MC Clínica Baviera, S.A.€53.80€4910% above18.7x45.9%8571

Sector report card

Where PSNL ranks against its sector peers on each metric.

Computing percentiles…
  • Business Wire•Aug 4, 2026
    Personalis Reports Second Quarter Results and Recent Highlights
  • Business Wire•Jun 9, 2026
    Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
  • Business Wire•Jun 2, 2026
    Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
1 more press releases · full archive on Investor+.INVESTOR
40 filings
October 2026
Oct 6
8-KCurrent reportPeriod 2026-10-02
View on SEC →
September 2026
Sep 22
Form 4Insider transactionPeriod 2026-09-18
View on SEC →
Sep 22
Form 4Insider transactionPeriod 2026-09-18
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR